FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2765185887> ?p ?o ?g. }

• W2765185887 endingPage "A479" @default.
• W2765185887 startingPage "A479" @default.
• W2765185887 abstract "To evaluate the cost-effectiveness of empagliflozin, in addition to standard of care (SoC), for the treatment of adult patients with Type 2 diabetes mellitus (T2DM) and high cardiovascular risk (CV) in Greece. A health economic model was used to project clinical and economic outcomes of patients receiving empagliflozin plus SoC compared with those receiving SoC alone over a lifetime horizon. Long-term CV and renal event rates were derived from patient level data from EMPA-REG-OUTCOME trial by fitting time-dependent parametric survival functions. 5,000 individual patient profiles randomly sampled from the trial were simulated using a time to event approach. Model extrapolated outcomes included life years (LYs), quality-adjusted life years (QALYs), costs as well as incremental cost-effectiveness ratios (ICERs). Following a Greek third-party payer perspective, only direct medical costs related to drug acquisition as well as fatal and non-fatal developed diabetes-related complications were considered (€ 2016). Resource consumption associated with each treatment was based on experts’ advice. Cost units and utility data were extracted from literature and publicly available official sources. Sensitivity analyses explored the impact of changes in input data. Over a patient’s lifetime, empagliflozin was predicted to result in longer mean survival (14.01 LY versus 11.87 LY with SoC) and reduced rate of clinical events accumulating 7.75 QALYs versus 6.83 QALYs on SoC alone at additional costs of €4,235. The generated ICER of empagliflozin was €4,633 per QALY gained. One-way sensitivity analysis confirmed empagliflozin cost-effective profile. At the defined willingness-to-pay threshold of €34,000 per QALY gained, probabilistic sensitivity analysis showed that empagliflozin was estimated to have a 100% probability of being cost-effective relative to SoC. Empagliflozin added to SoC was estimated to be a highly cost-effective treatment option for the treatment of T2DM in adults with increased CV disease risk in Greece." @default.
• W2765185887 created "2017-11-10" @default.
• W2765185887 creator A5014525409 @default.
• W2765185887 creator A5018882870 @default.
• W2765185887 creator A5043495575 @default.
• W2765185887 creator A5045733302 @default.
• W2765185887 creator A5072838496 @default.
• W2765185887 creator A5073478319 @default.
• W2765185887 creator A5080008170 @default.
• W2765185887 date "2017-10-01" @default.
• W2765185887 modified "2023-09-26" @default.
• W2765185887 title "Cost-Effectiveness of Empagliflozin For The Treatment of Patients With Type 2 Diabetes Mellitus At Increased Cardiovascular Risk In Greece" @default.
• W2765185887 doi "https://doi.org/10.1016/j.jval.2017.08.455" @default.
• W2765185887 hasPublicationYear "2017" @default.
• W2765185887 type Work @default.
• W2765185887 sameAs 2765185887 @default.
• W2765185887 citedByCount "0" @default.
• W2765185887 crossrefType "journal-article" @default.
• W2765185887 hasAuthorship W2765185887A5014525409 @default.
• W2765185887 hasAuthorship W2765185887A5018882870 @default.
• W2765185887 hasAuthorship W2765185887A5043495575 @default.
• W2765185887 hasAuthorship W2765185887A5045733302 @default.
• W2765185887 hasAuthorship W2765185887A5072838496 @default.
• W2765185887 hasAuthorship W2765185887A5073478319 @default.
• W2765185887 hasAuthorship W2765185887A5080008170 @default.
• W2765185887 hasBestOaLocation W27651858871 @default.
• W2765185887 hasConcept C126322002 @default.
• W2765185887 hasConcept C134018914 @default.
• W2765185887 hasConcept C177713679 @default.
• W2765185887 hasConcept C194828623 @default.
• W2765185887 hasConcept C2775887513 @default.
• W2765185887 hasConcept C2777180221 @default.
• W2765185887 hasConcept C2910068830 @default.
• W2765185887 hasConcept C555293320 @default.
• W2765185887 hasConcept C71924100 @default.
• W2765185887 hasConceptScore W2765185887C126322002 @default.
• W2765185887 hasConceptScore W2765185887C134018914 @default.
• W2765185887 hasConceptScore W2765185887C177713679 @default.
• W2765185887 hasConceptScore W2765185887C194828623 @default.
• W2765185887 hasConceptScore W2765185887C2775887513 @default.
• W2765185887 hasConceptScore W2765185887C2777180221 @default.
• W2765185887 hasConceptScore W2765185887C2910068830 @default.
• W2765185887 hasConceptScore W2765185887C555293320 @default.
• W2765185887 hasConceptScore W2765185887C71924100 @default.
• W2765185887 hasIssue "9" @default.
• W2765185887 hasLocation W27651858871 @default.
• W2765185887 hasOpenAccess W2765185887 @default.
• W2765185887 hasPrimaryLocation W27651858871 @default.
• W2765185887 hasRelatedWork W135978600 @default.
• W2765185887 hasRelatedWork W1563850031 @default.
• W2765185887 hasRelatedWork W2136047525 @default.
• W2765185887 hasRelatedWork W2233866314 @default.
• W2765185887 hasRelatedWork W2383009242 @default.
• W2765185887 hasRelatedWork W2415759662 @default.
• W2765185887 hasRelatedWork W2534023429 @default.
• W2765185887 hasRelatedWork W2981498847 @default.
• W2765185887 hasRelatedWork W3028699398 @default.
• W2765185887 hasRelatedWork W3036934084 @default.
• W2765185887 hasVolume "20" @default.
• W2765185887 isParatext "false" @default.
• W2765185887 isRetracted "false" @default.
• W2765185887 magId "2765185887" @default.
• W2765185887 workType "article" @default.